A61K 40/4201
Neoantigens
Official title: {Neoantigens}
A61K40/4201 (Neoantigens) appears on 74 US grants and 276 published applications in this corpus.
Search patents in A61K- Granted patents
- 74
- Published applications
- 276
- Assignees
- 150
- Inventors
- 537
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 4 |
| 2018 | 0 | 2 |
| 2019 | 1 | 19 |
| 2020 | 6 | 30 |
| 2021 | 5 | 35 |
| 2022 | 7 | 39 |
| 2023 | 10 | 39 |
| 2024 | 10 | 44 |
| 2025 | 21 | 36 |
| 2026 | 14 | 25 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of isolating T cells and T-cell receptors from peripheral blood by single-cell analysis for immunotherapy6 Oct 2026US 12,753,437 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- T cell receptors specific for a mutant form of the RET oncogene and uses thereof8 Sep 2026US 12,729,370 B2Providence Health & Services - Oregon
- Cancer antigens and methods14 Jul 2026US 12,680,105 B2Enara Bio Limited
- Anti-cancer vaccines and related therapy7 Jul 2026US 12,674,179 B2The Institute of Cancer Research: Royal Cancer Hospital
- T cell manufacturing compositions and methods16 Jun 2026US 12,653,887 B2Biontech US Inc.
- Tumor-Specific Neoantigens and Methods of Using the Same24 Sep 2026US 2026/0285928 A1Geneos Therapeutics, Inc.
- Anti-cancer vaccines and related therapy24 Sep 2026US 2026/0286395 A1The Institute of Cancer Research: Royal Cancer Hospital
- Identification of neoantigen-reactive t cell receptors17 Sep 2026US 2026/0273054 A1Alaunos Therapeutics, Inc.
- Fusion neoantigens for use in cancer vaccines, antibody therapy, and cell therapies27 Aug 2026US 2026/0250358 A1The Cleveland Clinic Foundation
- Tcr molecules targeting kras mutation, cells and use of tcr molecules and cells20 Aug 2026US 2026/0240907 A1Beijing Dcty Biotech Co., Ltd.
Most cited
By later US patents
- Binding molecules binding PD-L1 and LAG-312US 11,214,620 B2F-star Therapeutics Limited · 2022
- Anti-KRAS-G12D T cell receptors7US 10,611,816 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2020
- Methods for profiling the t cell repertoire5US 10,993,997 B2Dana-Farber Cancer Institute, Inc. · 2021
- Anti-KRAS-G12D T cell receptors5US 11,208,456 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2021
- Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors3US 10,350,243 B2Memorial Sloan Kettering Cancer Center · 2019